NAD Precursors Monitoring Bundle: Lab Panels, Timelines, and Clinical Checkpoints for Prescribers
HealthRX.com
No labeled monitoring exists for NMN or NR
Key numbers
- 250 mgNMN daily dose in 30 healthy adults for 12 weeks, with no laboratory abnormalitiesSource: pubmed.ncbi.nlm.nih.gov, as cited Oct 30, 2026
- 1,250 mgNMN daily dose in 31 healthy adults for up to 4 weeks, with no severe adverse eventsSource: pubmed.ncbi.nlm.nih.gov, as cited Oct 30, 2026
- 1,000 mg twice dailyNR twice-daily dose in 40 sedentary men with obesity over 12 weeks, with normal safety blood testsSource: pubmed.ncbi.nlm.nih.gov, as cited Oct 30, 2026
- 1,500 mg twice dailyNR twice-daily dose in 10 Parkinson's patients for 4 weeks, with no moderate or severe adverse eventsSource: pubmed.ncbi.nlm.nih.gov, as cited Oct 30, 2026
- 21 daysNR taken for 21 days in 12 older men did not raise muscle NAD+ or improve muscle functionSource: pubmed.ncbi.nlm.nih.gov, as cited Oct 30, 2026
From the public record
Human studies of NAD+ precursor effects on blood NAD+ levels
Airhart 2017, a non-randomized pharmacokinetic study of 8 healthy volunteers, reported whole-blood NAD+ rose 100% at steady state on oral nicotinamide riboside. Trętowicz 2026, across seven human cohorts, reported whole-blood NAD+ stable with age and lifestyle but changed with nicotinamide riboside.
| Measure | Value | Note |
|---|---|---|
| Human: Airhart 2017, non-randomized PK study, 8 healthy volunteers | Blood NAD+ increased 100% | Whole-blood NAD+ increased by 100% at steady state, and oral NR was well tolerated. PMID 29211728 |
| Human: Trętowicz 2026, blood measurement study, seven independent human cohorts | No change with age or lifestyle | Whole-blood NAD+ stayed stable with age and lifestyle but rose with nicotinamide riboside. PMID 42135539 |
| Human: Euro 2026, enzymatic cycling assay study, Healthy aged 18-70 years | Blood NAD+ rose 4-6-fold | High-dose nicotinic acid raised blood NAD+ 4-6-fold; follow-up is needed in trials. PMID 42628241 |
How this was calculated
PubMed title and abstract search on 2026-11-13 for NAD+, NAD, nicotinamide adenine dinucleotide with laboratory monitoring, lab monitoring, blood chemistry, blood test: 267 records, 15 abstracts read, 3 listed, each row summarising its own abstract.
NAD precursor monitoring labs and clinical checkpoints: 3 human, 0 animal and 0 laboratory studies of 267 PubMed records.
At a glance
- Regulatory status / oral dietary supplements; neither is FDA-approved [1]
- Trial monitoring / blood counts, chemistry and urine were assessed in some studies [3][4]
- Study duration / short; long-term safety data are lacking [2]
- Labs used in trials / hematology, blood biochemistry, urinalysis [4][3]
- Drug-interaction studies / none identified in a 2023 review [2]
- Groups not studied / pregnancy, breastfeeding, children, cancer, kidney or liver disease [2]
- Injectable NAD+ / compounded; no NAD+ drug is FDA-approved for aging or wellness [5]
Does anything specify monitoring?
NMN and NR are sold in the US as oral dietary supplements, and no NAD+ precursor product is FDA-approved for aging or any disease [1]. There is no prescribing label, so the only monitoring information comes from what the trials below checked.
What people on Reddit report
Reddit accounts from people taking NAD precursors who discuss whether to test NAD levels and how blood and brain levels respond over time.
To be honest, no one really knows if the "I feel better" results are placebo or not. Your best bet is to just get your intracellular NAD+ levels tested, preferably both before and after a few months of use. I'm sure there are multiple places that do it.Read the source discussion
It's interesting that blood NAD levels increased significantly and quickly (much more with NR), but that brain NAD levels did not increase during the first week. This suggests that NAD replenishment results could take weeks or more, at least in some tissues.Read the source discussion
Questions worth asking
What the trials checked
The trials reported no clinically relevant changes in the laboratory measures they assessed at the studied doses [3][6][4][7].
- NMN 1,250 mg daily for up to 4 weeks in 31 healthy adults: no severe adverse events and no changes beyond physiological variation in hematology, biochemistry, urine or body composition [4].
- NMN 250 mg daily for 12 weeks in 30 healthy adults: no laboratory abnormalities and no obvious adverse effects [3].
- NMN 300, 600 or 900 mg daily for 60 days in 80 middle-aged adults: no safety issues [6].
- In a 12-week trial of 40 sedentary men with obesity, those assigned to NR took 1,000 mg twice daily; there were no serious adverse events and safety blood tests were normal [7].
- NR 1,500 mg twice daily for 4 weeks in 10 people with Parkinson's disease (10 others took placebo): no moderate or severe adverse events [8].
The available studies were short and had small sample sizes, which limits interpretation of long-term safety [2].
Blood chemistry and cancer concerns
Blood chemistry was among the laboratory measures these trials assessed, and they reported no clinically relevant changes at the doses tested [3][6][4][7].
Cancer risk with long-term NAD+ boosting remains a theoretical concern; human data addressing it are lacking [2].
Drug interactions and homocysteine
A 2023 review identified no human drug-interaction studies of NMN or NR [2].
In a four-week trial of 20 people with Parkinson's disease, 10 took NR 1,500 mg twice daily and 10 took placebo. NR recipients had a slight initial rise in serum homocysteine; the authors judged the methyl donor pool intact [8]. In that trial, an apparent symptom-score improvement was also associated with a shorter interval since the last levodopa dose, so the clinical result is confounded [8].
Blood NAD+ versus tissue NAD+
Oral NMN and NR raise NAD+ in blood [3][6][9]. A rise in blood NAD+ does not establish that muscle NAD+ also rose: in 12 older men, 21 days of NR did not raise muscle NAD+ or improve measured muscle function [10].
Injectable NAD+
Injectable or IV NAD+ is a compounded product, and no NAD+ drug is FDA-approved for aging or wellness [5]. The trials above used oral NMN or NR, so these findings do not apply to injected NAD+.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
What tests did the NMN and NR trials use?
Do NMN or NR interact with prescription drugs?
Is blood NAD+ testing useful for monitoring?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What are the precursors for NAD+?
The two precursors named are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both are sold in the US as oral dietary supplements, and neither is FDA-approved for aging or any disease.
Why is NAD+ controversial?
The concerns are that long-term safety is not established and that cancer risk is unresolved. Cancer risk with long-term NAD+ boosting remains a theoretical concern, and human data addressing it are lacking. The available studies were short and had small sample sizes.
Who takes nad+NR and what benefits have you noticed?
The trials enrolled healthy adults, 40 sedentary men with obesity, and people with Parkinson's disease. No established benefit is reported. An apparent symptom-score improvement in the Parkinson's trial was associated with a shorter interval since the last levodopa dose, so the clinical result is confounded.
References
Show all 12 referencesHide references
- Official web page.
- Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. J Gerontol A Biol Sci Med Sci. 2023;78(12):2435-2448.
- Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9:868640.
- Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12(1):14442.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43.
- Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353.
- Berven H, Kverneng S, Sheard E, Søgnen M, Af Geijerstam SA, Haugarvoll K, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023;14(1):7793.
- Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
- Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6.
- Reddit participants. NAD+ precursors longterm benefits (r/Biohackers). Accessed 2026-11-10.
- Reddit participants. NR produced an about 2.3-fold higher increase in blood NAD levels compared to NMN (r/NicotinamideRiboside). Accessed 2026-11-10.